Diane L. Reidy-Lagunes
Expertise in
18
conditions

Dr. Diane L. Reidy-Lagunes

Hematology Oncology | Hematology | Oncology
20 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
18
conditions
20 Duke Medicine Cir, 
Durham, NC 

Overview

Diane Reidy-Lagunes is a Hematologist Oncology specialist and a Hematologist practicing medicine in Durham, North Carolina.

Dr. Reidy-Lagunes is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

She is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 5 clinical trials. Dr. Reidy-Lagunes is currently accepting new patients.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Duke University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LEE011, Everolimus
Study Phase: Phase 2
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: August 04, 2020
Intervention Type: Other
A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: June 25, 2019
Intervention Type: Other
View 4 Less Clinical Trials

101 Total Publications

Dual pancreatic carcinomas: clonally related or independent primaries?
Dual pancreatic carcinomas: clonally related or independent primaries?
Journal: NPJ precision oncology
Published: January 13, 2026
Similar Doctors
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Referral may be required

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (5.6 miles away)
984-974-2695
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist and an Oncologist practicing medicine in Chapel Hill, North Carolina. Dr. Key is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease. Dr. Key is currently accepting new patients.

Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Referral may be required

Duke University Hospital

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-668-6288
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist and an Oncologist practicing medicine in Durham, North Carolina. Dr. Ashley is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Expertise in
29
conditions
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology
Expertise in
29
conditions
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Duke Cancer Center Sarcoma Clinic

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-613-5550
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I am a medical oncologist specializing in bone and soft tissue cancers called sarcomas. Sarcomas occur throughout the body, so I collaborate closely with colleagues from other specialties in a multidisciplinary team. I view my role in caring for someone's cancer as as privilege and strive to work together with each patient to ensure the best treatment decisions are made, all the while embracing each person's uniqueness as an individual. I see adult patients of all ages, but have a particular interest in the unique challenges facing a young adults with cancer. When I'm not working, you can find me exploring the outdoors with my family, traveling, and cooking. Dr. Grilley-Olson is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Rhabdomyosarcoma Embryonal. Dr. Grilley-Olson is board certified in American Board Of Internal Med, Medical Oncology. Dr. Grilley-Olson is currently accepting new patients.

Frequently Asked Questions about Dr. Diane L. Reidy-Lagunes

How do I make an appointment with Dr. Diane L. Reidy-Lagunes?

You can book an appointment with Dr. Diane L. Reidy-Lagunes by calling their office at 919-681-6900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Diane L. Reidy-Lagunes a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Diane L. Reidy-Lagunes is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Diane L. Reidy-Lagunes specialize in?

While Dr. Diane L. Reidy-Lagunes is a Hematology Oncology, they have specific expertise in Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, and Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Diane L. Reidy-Lagunes participate in research or clinical trials?

Yes. Dr. Diane L. Reidy-Lagunes has published 101 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Diane L. Reidy-Lagunes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Diane L. Reidy-Lagunes accept my insurance?

Dr. Diane L. Reidy-Lagunes accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 919-681-6900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reidy-Lagunes's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile